Results showed that at 6 months post-surgery, at least 1-, 2-, and 3-line gains in best-corrected distance were achieved in 97.1%, 68.6%, and 51.4% of operated eyes, respectively.

RayTrace has been utilized globally by surgeons since 2008.

Catch up on what happened in optometry during the week of January 13-January 17.

Previously, ClearVision Optical was Revo’s ECP channel distributor for 8 years.

City Therapeutics will develop a novel RNAi clinical candidate toward a specific disease target for intravitreal administration.

Focused inSights 2024: Frame Buyers found that 78% of providers display between 200 and 1200 frames on their boards, with 70% of providers updating their inventory quarterly.

The award program includes Transitions Healthy Sight Ambassador, Eyecare Practice of the Year, Retailer of the Year, and Channel Partner of the Year awards.

WAVE Eye Care was developed by EyePrint Prosthetics, Advanced Vision Technologies (AVT), and WAVE Contact Lens System.

The guideline, titled "Care of the Patient with Primary Open-Angle Glaucoma," was developed by the AOA Evidence-based Optometry Guideline Development Group.

The company's lead product candidate Duravyu (vorolanib intravitreal insert), f/k/a EYP-1901, is anticipating topline data from several clinical trials in 2026.

The investigators used National Health and Nutrition Examination Survey data in a cross-sectional study to determine the association between Dietary Inflammatory Index and non-refractive visual impairment from diseases other than cataract and age-related macular degeneration.

Whitecap is currently developing 2 therapies for potential use in glaucoma and geographic atrophy.

The company will prioritize its cash in funding its ongoing Phase 1/2 PRISM clinical trial and Phase 3 4FRONT program.

The webinar will overview new offerings, details about the show’s updated brand and new exhibit hall layout, special events, and announcements regarding this year’s keynote speaker and other main stage sessions.

The new standards touch on alignment, terminology, expectations, and adherence, according to the council.

Nocturnal hypoxia could be a new additional modifiable risk factor for nAMD.

With this addition, Zeiss completes the Corneal Refractive Workflow, which already includes Visumax 800 and SMILE pro.

The application was refiled following a December 20, 2024, meeting between the US Food and Drug Administration (FDA) and Astellas.

Katie Rachon, OD, FAAO, Dipl ABO, shares her excitement for the upcoming conference and what it means for an optometrist's toolbox.

Catch up on what happened in optometry during the week of January 6-January 10.